BEIGF (BeOne Medicines) Tariff Resilience Score: 8/10 (As of Jul. 05, 2026)


BEIGF BeOne Medicines Ltd BEIGF
61 GF Score
Price $21.95
GF Value $27.07
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is BeOne Medicines Tariff Resilience Score?

BeOne Medicines BEIGF 61 Tariff Resilience Score is 8 as of Jul. 05, 2026. GuruFocus rates BEIGF with a GF Score™ of 61/100 and a GF Value™ of $27.07 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 1,369 Biotechnology companies, BeOne Medicines ranks better than 98.69% on this metric.

BeOne Medicines has the Tariff Resilience Score of 8, which implies that the company might have Highly Resilient.

BeOne Medicines has Biopharmaceutical company with significant R&D and manufacturing in China. Global sales could face tariff challenges, but strong partnerships and local production mitigate risks.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes BeOne Medicines might have Highly Resilient.

BeOne Medicines  (OTCPK:BEIGF) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

BeOne Medicines Tariff Resilience Score Related Terms

BEIGF vs MRNA, RPRX, ROIV: Tariff Resilience Score Comparison

For the Biotechnology subindustry, BeOne Medicines's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BeOne Medicines Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BeOne Medicines's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where BeOne Medicines's Tariff Resilience Score falls into.


BEIGF
61GF Score
BeOne Medicines Ltd BEIGF
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 8 mean?
BeOne Medicines (BEIGF) has a Tariff Resilience Score of 8 as of Jul. 05, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, BeOne Medicines ranks #18 out of 1369 companies in the Biotechnology industry, placing it in the top 1.3%.
Is BeOne Medicines' Tariff Resilience Score too high?
BeOne Medicines' current Tariff Resilience Score is 8. The Biotechnology industry median Tariff Resilience Score is 4.00. BeOne Medicines' value of 8 is 100% above this industry median. Based on the distribution chart, BeOne Medicines ranks #18 out of 1369 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, BeOne Medicines has a GF Score™ of 61/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does BeOne Medicines' Tariff Resilience Score compare to MRNA and RPRX?
According to the Biotechnology industry distribution chart, BeOne Medicines ranks #18 out of 1369 companies for Tariff Resilience Score. This places BeOne Medicines in the top 1% of its industry — outperforming the majority of peers. The industry median Tariff Resilience Score is 4.00. BeOne Medicines' value of 8 is 100% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,369 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BeOne Medicines's current Tariff Resilience Score of 8 is 100% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BeOne Medicines's current Tariff Resilience Score is 8. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BeOne Medicines stock overvalued right now?
Based on GuruFocus' analysis, BeOne Medicines (BEIGF) is currently considered Modestly Undervalued. The stock's GF Value™ is $27.07, compared to a current price of $21.95 — trading 18.9% below its estimated fair value. The current Tariff Resilience Score is 8 and 100% above the Biotechnology industry median of 4.00. BeOne Medicines' overall GF Score™ is 61/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For BeOne Medicines (BEIGF), the current Tariff Resilience Score is 8 as of Jul. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BeOne Medicines (BEIGF) Overvalued in 2026?

Based on GuruFocus' analysis, BeOne Medicines stock appears to be undervalued. The current stock price of $21.95 is trading 18.9% below its estimated GF Value™ of $27.07. GuruFocus considers BeOne Medicines to be Modestly Undervalued.

Key valuation signals for BEIGF:

  • Tariff Resilience Score: 8
  • GF Value™: $27.07 vs. price of $21.95 (18.9% below fair value)
  • GF Score™: 61/100 with 4 warning signs
  • Industry Position: 100% above the Biotechnology median (#18 of 1369)

No single metric tells the full story. See the BEIGF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BeOne Medicines Business Description

Address c/o BeOne Medicines I GmbH, 94 Aeschengraben 27, 21st Floor, Basel, CHE, 4051
Formerly known as BeiGene and founded in 2010 in Beijing, BeOne is a commercial-stage biotech firm that produces oncology therapeutics. The company's main product is Brukinsa, which is a small-molecule drug that treats multiple forms of Non-Hodgkin lymphoma and leukemia. The company conducts drug discovery, runs global clinical trials, and manufactures drugs independently. As of 2025, Brukinsa made up for 74% of total revenue, while it has two other approved commercialized drugs in its portfolio, Beqalzi and Tevimbra. While Brukinsa has a global leadership, the other two drugs generate revenue mostly from China. Based on Brukinsa, BeOne competes with AbbVie and AstraZeneca mainly. The company also has more than 50 drugs in clinical trials in its active pipeline, focused on other cancers.
61GF Score

Get the complete analysis for BEIGF

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$21.95
Price
$27.07
GF Value